Because NAb+ status is associated with decreased effectiveness of IFN-b, knowing this status for patients can aid in clinical decision-making. "For example, if a patient is having frequent attacks on interferon beta-1a and has neutralizing antibodies ... it is probable that the patient is not having a response in vivo to the drug."⁵ In such a case, a physician could evaluate changing therapies. The IFNB study suggested that "[c]ertainly one piece of evidence that might help clinicians make such a decision would be the serum titer of NAbs."⁵

In this way, a NAb assay, considered in conjunction with clinical activity and MRI evidence, can help to eliminate clinical guesswork that "risks the possibility of removing patients from therapy who remain NAb- and continue to benefit fully from treatment, even if some MS activity may continue."⁵